Company Focus
AstraZeneca
Latest AstraZeneca News
Biotechnology
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
Related News
Insights
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Latest News & Features of interest to AstraZeneca
Pharmaceutical
US rare disease drug focussed company Zevra Therapeutics saw its shares rise nearly 43% to $9.00 in after-hours trading on Friday as it announced a positive development for its arimoclomol. 5 August 2024
Biotechnology
Clinical trial results featured heavily in the news last week, first with Dutch biotech NewAmsterdam releasing data on its hypercholesterolemia candidate obicetrapib. US drug developer MacroGenics announced receipt of a $100 million milestone from Incyte relating to progress in its deal on Zynyz and updated on the development of prostate cancer drug vobra duo. Germany’s BioNTech announced top-line Phase II results of its mRNA cancer immunotherapy BNT111. Also, US pharma major Eli Lilly released new data on its GLP-1 drug tirzepatide – already marketed for diabetes and obesity under the trade names Mounjaro and Zepbound, respectively - in heart failure. 4 August 2024
Pharmaceutical
Pharma giants are vehemently opposing the Indian government's proposal to apply the trade margin rationalization (TMR) formula to certain drugs with the aim of reducing drug prices. 2 August 2024
Biotechnology
FibroGen (Nasdaq: FGEN) has announced it will lay off around 75% of its US staff following disappointing results from late-stage trials of pamrevlumab. 2 August 2024
Biotechnology
Dallas, Texas-based Instil Bio and China’s ImmuneOnco Biopharmaceuticals have announced a license and collaboration agreement. 2 August 2024
Pharmaceutical
Chugai Pharmaceutical says its Taiwan subsidiary (CPT) has obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Alecensa (alectinib) 2 August 2024
Biotechnology
Change in on the way at California’s Vir Biotechnology. 2 August 2024
Pharmaceutical
BridGene Biosciences is expanding its collaboration with Belgian firm Galapagos (Euronext: GLPG) to advance drug discovery for challenging cancer targets. 2 August 2024
Biotechnology
The US Food and Drug Administration (FDA) yesterday approved Jemperli (dostarlimab-gxly), from UK pharm major GSK. 2 August 2024
Biotechnology
Valneva (Euronext Paris: VLA) and LimmaTech Biologics have entered into a strategic partnership and exclusive licensing agreement to develop, manufacture, and commercialize Shigella4V. 2 August 2024
Latest In Brief for AstraZeneca
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Latest Related Ones To Watch News
Bristol Myers Squibb has scored a major legal victory as a judge in New York dismissed a $6.4 billion lawsuit related to its acquisition of cancer company Celgene. 1 October 2024
24 September 2024
24 September 2024
19 September 2024
5 September 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze